CMS has significantly boosted the amount that Medicare will pay for administering COVID-19 vaccines, a move that appears to be a positive development for health care providers and retail pharmacies but a potential headwind for commercial health insurers.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.